Abstract:Background Prescribers have an increasing range of inhaled antimicrobial formulations to choose from when prescribing both eradication and chronic suppression regimens in cystic fibrosis (CF). This study aimed to investigate the decision-making process behind prescribing of inhaled antimicrobials for Pseudomonas aeruginosa infections. Methods A questionnaire was developed using Microsoft Forms and then forwarded to 57 Principal Investigators (PIs), at each of the CF centres within the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). Data collection occurred between November 2021 and February 2022. Results The response rate was 90 % ( n = 51/57 PIs), with at least 50 % of CF centers in each of the 17 countries represented in the ECFS-CTN. Physicians used a median of eight factors in their decision-making process with delivery formulations (92.2 %), adherence history (84.3 %), and antibiotic side-effect profile (76.5 %) often selected. Nebulised tobramycin or colistin were frequently selected as the inhaled antimicrobial in first-line eradication ( n = 45, 88.2 %) and chronic suppression regimens ( n = 42, 82.4 %). Combination regimens were more often chosen in eradication (first-line: n = 35, 68.6 %, second-line: n = 34, 66.7 %) and later chronic suppression regimens (third-line: n = 27, 52.9 %) than monotherapy. For pwCF also prescribed CFTR modulator therapies, most PIs did not alter inhaled antimicrobial regimens ( n = 40, 78.4 %), with few pwCF ( n = 18, 35.3 %) or PIs ( n = 10, 19.6 %) deciding to stop inhaled antimicrobials. Conclusions The inhaled antimicrobial prescribing decision-making process is multifactorial. Nebulised tobramycin or colistin are often used in initial eradication and chronic suppression regimens. To date, CFTR modulator therapy has had a limited impact on the prescribing of inhaled antimicrobial regimens.

Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis

Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis – where do we stand?

Inhaled Antibiotic Therapy in Chronic Respiratory Diseases

Pseudomonas aeruginosa in the Cystic Fibrosis Lung

Antibiotic treatment of bacterial lung infections in cystic fibrosis

Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens

Tobramycin safety and efficacy review article

The airway microbiome in cystic fibrosis and implications for treatment

Molecular Mechanisms of Staphylococcus and Pseudomonas Interactions in Cystic Fibrosis

A Review of Phase IV Trials

Cystic fibrosis lung environment and Pseudomonas aeruginosa infection

Bacteriophage therapy for infections in CF

Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives

Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections

Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe

Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients’ Lung

Antimicrobial molecules in the lung: formulation challenges and future directions for innovation

New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis

Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections